Predictors for Improvement in Patient-Reported Outcomes in Complement Inhibitor–Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Eculizumab and Ravulizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria
Ann Hematol 2024 Jan 01;103(1)5-15, H Schrezenmeier, A Kulasekararaj, L Mitchell, RP de Latour, T Devos, S Okamoto, R Wells, E Popoff, A Cheung, A Wang, I Tomazos, Y Patel, JW LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.